5 ways healthcare hopes to improve prior authorization

Prior authorization is often listed as one of the biggest hassles for many healthcare facilities, with plenty of calls for collaboration between major associations to streamline the onerous process. Those efforts have now led to a consensus statement from six groups on their shared goals for preapproving patients’ medical treatments.

The American Hospital Association, America’s Health Insurance Plans, American Medical Association, American Pharmacists Association (APhA), Blue Cross Blue Shield Association and Medical Group Management Association recommended focusing on five areas of improvement:

  1. Selective application of prior authorization
  2. Program review and volume adjustment
  3. Transparency and communication
  4. Continuity of patient care
  5. Automation to improve transparency and efficiency

“Meeting health plan proprietary authorization requirements consume significant time for both clinical and administrative personnel, diverting staff away from providing direct patient care, and costing practices countless dollars to administer,” Anders Gilberg, MGMA’s senior vice president of government affairs, said in a statement. “Most importantly, the prior authorization process can result in delayed or denied patient care.”

Read more at Cardiovascular Business:

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.